Randomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of COVID-19, the majority heavily-infected with the UK variant.ADVERTISEMENTPatients with a self-administered nasal spray application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hoursTrial concluded that treatment accelerated clearance of SARS-CoV-2 by a factor of 16-fold versus a placeboRandomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of COVID-19, the majority heavily-infected with the UK variantNo adverse events were recorded in the groupSubmission for Emergency Use in the UK and Canada for the treatment...